What payers will ask
Is the clinical benefit the kind payers reward? — Clinical effectiveness
Cipaglucosidase alfa plus miglustat shows moderate benefit over standard treatments, particularly in improving walking and breathing in the short term. However, the long-term effects remain uncertain, and the evidence is primarily based on indirect comparisons with existing therapies.
Does the economic case hold at the expected price? — Cost effectiveness
Cipaglucosidase alfa plus miglustat is considered cost-effective compared to existing treatments, with a positive net health benefit at the £20,000 per QALY threshold. However, uncertainties in the economic model and treatment sequencing were noted.
Is there quality-of-life evidence payers weigh? — Quality of life
The treatment has been reported to improve quality of life, with patient experts noting significant benefits such as improved stamina and reduced fatigue. However, the evidence is based on subjective reports and lacks robust quantitative data.
Does the safety profile hold up for payers? — Safety and Adverse Effects
The safety profile of cipaglucosidase alfa plus miglustat is comparable to existing enzyme replacement therapies, with mostly mild to moderate adverse events reported. There are no significant safety concerns that would undermine its use.
Was the drug compared against what payers expect? — Comparator Selection
The treatment was primarily compared to alglucosidase alfa, with indirect comparisons to avalglucosidase alfa. While alglucosidase alfa is a relevant comparator, the lack of direct evidence against AVAL limits the robustness of the comparisons.
Is the population defined the way payers need it? — Patient Population and Subgroups
The trial populations largely reflect the real-world population of patients with late-onset Pompe disease, although there are some exclusions at the extremes of disease severity. The evidence is considered generalizable to Healthcare practice.
Does the drug fit how care is delivered and paid for? — Care Pathway Integration
Cipaglucosidase alfa plus miglustat can be integrated into existing treatment pathways with minor adjustments. The treatment is expected to be available for both newly diagnosed patients and those switching from other therapies.
Are the wider system costs understood? — Resource Use and Cost Implications
The treatment is expected to have a manageable budget impact, with potential cost savings due to its effectiveness compared to existing therapies. However, uncertainties in resource use estimates were noted.
Would the evidence survive payer scrutiny? — Evidence Quality and Robustness
The evidence is based on a phase 3 RCT and additional studies, providing a strong foundation for decision-making. However, some limitations in data completeness and long-term follow-up were acknowledged.
How exposed is the case to uncertainty? — Uncertainty, Sensitivity, and Broader Impacts
There are notable uncertainties regarding the long-term efficacy and cost-effectiveness of cipaglucosidase alfa plus miglustat, particularly in the absence of direct comparative data with AVAL. This uncertainty may impact its broader adoption.
